Although targeted inhibitors of mutant IDH have shown promise in IDH mutant acute leukaemia patients, no benefits have been obtained for patients affected by gliomas, despite the reduction in D2-HG after treatment with inhibitors. The gene discussed is IDH2; the disease is central nervous system cancer.